Literature DB >> 9624252

Inhibition of fibroblast collagen synthesis and proliferation by levamisole and 5-fluorouracil.

J W de Waard1, B M de Man, T Wobbes, C J van der Linden, T Hendriks.   

Abstract

Experimental studies indicate that anastomotic healing in the intestine is compromised by the immediate postoperative administration of 5-fluorouracil and levamisole. Since fibroblast functions are crucial to healing, we investigated the effects of (combinations of) both drugs on proliferation and collagen synthesis of rat skin fibroblasts in vitro. Proliferation was measured in actively dividing cells by cellular [3H]thymidine uptake and collagen synthesis in non-dividing cells by [3H]proline incorporation into collagenase-digestible protein. 5-Fluorouracil strongly and significantly (P < 0.05) reduced DNA synthesis and collagen synthesis at concentrations of 1 microM or more. The latter effect was not specific for collagen since total protein production was affected similarly. Both effects depended on the duration of exposure to the drugs. Levamisole also inhibited fibroblast proliferation dose-dependently, but less effectively than 5-fluorouracil: 50% inhibition was observed at approximately 0.1 mM. Collagen synthesis was unaffected by levamisole. If levamisole was added together with a low (0.1 microM) concentration of 5-fluorouracil, which in itself did not decrease thymidine incorporation, levamisole's antiproliferative effects became apparent at concentrations as low as 1 microM. A similar effect, but at a much higher concentration (1 mM) was noted on fibroblast collagen synthesis. These results indicate that levamisole potentiates 5-fluorouracil effects in fibroblast cultures and that direct effects of these drugs, alone or in combination, on fibroblast proliferation and collagen synthesis may be responsible for their negative influence on wound repair.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624252     DOI: 10.1016/s0959-8049(97)00352-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Levamisole induced apoptosis in cultured vascular endothelial cells.

Authors:  M Artwohl; T Hölzenbein; L Wagner; A Freudenthaler; W Waldhäusl; S M Baumgartner-Parzer
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Single-Cell Protein and Transcriptional Characterization of Epiretinal Membranes From Patients With Proliferative Vitreoretinopathy.

Authors:  Yannik Laich; Julian Wolf; Rozina Ida Hajdu; Anja Schlecht; Felicitas Bucher; Laurenz Pauleikhoff; Martin Busch; Gottfried Martin; Henrik Faatz; Saskia Killmer; Bertram Bengsch; Andreas Stahl; Albrecht Lommatzsch; Günther Schlunck; Hansjürgen Agostini; Stefaniya Boneva; Clemens Lange
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-05-02       Impact factor: 4.925

3.  Is early post-operative treatment with 5-fluorouracil possible without affecting anastomotic strength in the intestine?

Authors:  B M van der Kolk; B M de Man; T Wobbes; T Hendriks
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

4.  Effects and safety of triamcinolone acetonide-controlled common therapy in keloid treatment: a Bayesian network meta-analysis.

Authors:  Zhenyu Zhang; Lihui Cheng; Ru Wang; Ying Cen; Zhengyong Li
Journal:  Ther Clin Risk Manag       Date:  2018-05-29       Impact factor: 2.423

Review 5.  Advancements in Regenerative Strategies Through the Continuum of Burn Care.

Authors:  Randolph Stone Ii; Shanmugasundaram Natesan; Christine J Kowalczewski; Lauren H Mangum; Nicholas E Clay; Ryan M Clohessy; Anders H Carlsson; David H Tassin; Rodney K Chan; Julie A Rizzo; Robert J Christy
Journal:  Front Pharmacol       Date:  2018-07-09       Impact factor: 5.810

6.  Novel Methacrylate-Based Multilayer Nanofilms with Incorporated FePt-Based Nanoparticles and the Anticancer Drug 5-Fluorouracil for Skin Cancer Treatment.

Authors:  Kristijan Skok; Tanja Zidarič; Kristjan Orthaber; Matevž Pristovnik; Nina Kostevšek; Kristina Žužek Rožman; Sašo Šturm; Lidija Gradišnik; Uroš Maver; Tina Maver
Journal:  Pharmaceutics       Date:  2022-03-22       Impact factor: 6.525

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.